Brain tumors (BTs) are among the most malignant forms of human cancer. Unfortunately, current treatments are often ineffective and produce severe side effects. Cytotoxic gene therapy is an alternative treatment strategy, with the potential advantages of reduced toxicity to normal brain tissue. Apoptosis-inducing ''death ligands'' Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) are genes with substantial cytotoxic activity in susceptible tumor cells. Here, we compared the effectiveness of Ad vectormediated delivery of Fas ligand-green fluorescent protein (FasL-GFP) fusion protein, human TRAIL, and both genes simultaneously. We examined a panel of 13 cell lines (eight derived from primary isolates) for susceptibility to Ad5-based vector infection and for sensitivity to FasL-and TRAIL-mediated apoptosis. All cell lines were efficiently transduced, but, as expected, varied in their sensitivity to ligand-induced apoptosis. Generally, sensitivity to FasL-GFP correlated with cell surface FasR levels, but no such correlation was seen for TRAIL and its functional receptors, DR4 and DR5. The vector expressing both FasL-GFP and TRAIL was more effective than either of the single-gene vectors at comparable transduction levels, and it was effective against a broader range of cell lines. In five cell lines, coexpression resulted in apoptosis levels greater than those predicted for strictly additive activity of the two death ligands. We believe that Ad vector-mediated delivery of multiple death ligands may be developed as a potential BT therapy, either alone or in conjunction with surgical resection of the primary tumor.
T umors of the brain, including anaplastic astrocytoma, glioma and glioblastoma multiforme, are among the most malignant forms of human cancer. Glioblastoma multiforme is a very aggressive tumor, with a uniform and profound morbidity. These tumors are rarely metastatic, but primary tumors are often extensively infiltrated into the surrounding normal tissue. Thus, while surgery is the primary choice of treatment, frequent relapses occur as a result of failure to remove all cancerous cells from the primary site completely. Other traditional treatments, such as radiation and chemotherapy, typically do not improve outcome. Gene therapy using Ad-mediated transfer of toxic genes into tumor cells promises an alternative treatment with the possibilities of reduced toxicity and minimal surgical damage to normal brain tissue. 1 However, the limitations of current gene therapy approaches are low transduction efficiency and a lack of effective glioma cell-killing genes. Vector-mediated deliveries of prodrug converting enzyme, such as thymidine kinase (TK) gene, have generated promising results in animal models. However, the therapeutic effects may be limited by low levels of prodrug penetration to the brain, a lack of bystander killing effects in cells that do not have gap junctions, and possible resistance to DNA synthesis inhibitors. 2 Recently, attempts have been made to force cancer cells to undergo apoptosis by transducing them with vectors carrying tumor suppressor genes such as p53 or Bax. [3] [4] [5] However, a number of tumors were found to be resistant to p53 activity. 3, 5 Therefore, the potential of other apoptosis-inducing genes needs to be evaluated. Two such proteins are the ''death ligands'' Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL).
Death ligands are members of the tumor necrosis factor (TNF) family. They are type 2 transmembrane proteins that form homotrimers on the cell surface through interactions localized in their extracytoplasmic domains. 6, 7 The best known family members are TNF-a, FasL and TRAIL, all of which are being investigated as potential cancer therapy agents. 8 TRAIL expression has been detected in a wide variety of human tissues, with the highest levels found in spleen, lung and prostate, but not in the brain or liver. 9 In contrast, high-level FasL expression is primarily restricted to cells of the immune system, such as activated T lymphocytes and NK cells. Receptors for these ligands are members of the TNF receptor superfamily, 6 ,10-12 many of which contain a ''death domain'' (DD). They are widely expressed on normal cells and are often found on tumor cells. The two primary functions of the FasR-FasL system are the maintenance of homeostasis in the immune system and the elimination of antigen-expressing target cells by cytotoxic T lymphocytes. [13] [14] [15] Binding of death ligands to DD-containing receptors initiates a common apoptotic pathway that involves aggregation of the receptors, which in turn causes the phosphorylation of amino acids in the DD. Phosphorylated DDs are recognized and bound by DD-containing adaptor proteins such as Fas-associated DD (FADD) and TNF-associated DD (TRADD). With the recruitment of caspase-8, death-inducing signaling complex (DISC) forms. 16 This signaling pathway culminates in activation of serine proteases known as caspases that break down both protein and DNA structures inside the cell, [17] [18] [19] ultimately leading to its disintegration. TRAIL interacts with several distinct but closely related receptors. Only two of them, TRAIL R1 (DR4) and TRAIL R2 (DR5), contain functional DDs and can initiate apoptosis upon ligand binding. 20 The others are thought to act as the decoy receptors (DcR) and their expression is thought to provide protection from TRAIL activity in normal cells. TRAIL is believed to be nontoxic to most normal cells in vitro or if delivered systemically in vivo, while at the same time inducing apoptosis in many tumor cell lines. Systemic administration of FasL, FasLexpressing vectors or activating anti-FasR mAbs results in severe and often lethal hepatotoxicity in animals, while similar administrations of TRAIL are not associated with damaging normal cells. [21] [22] [23] [24] Recently, studies have shown that both FasL and TRAIL can induce apoptosis in a number of tumor cell lines of various origins. [25] [26] [27] [28] [29] These proteins may have an advantage as therapeutics for brain tumors (BTs), since both they and their receptors are membrane proteins. Death ligand-induced apoptosis is mediated through cellcell contact, allowing the cell expressing the ligand to induce apoptosis in a number of surrounding receptorexpressing cells -a bystander effect not directly achieved with intracellular apoptosis-inducing proteins like p53 and Bax, and which does not require transport of prodrugs across the blood-brain barrier, as is the case for TK and cytosine deaminase.
Several published reports describe the construction and analysis of replication-defective recombinant Ad vectors that deliver FasL 25, 27, [30] [31] [32] [33] [34] or TRAIL. 35, 36 These vectors have not been uniformly successful against tumors established in animal models. 25, 27, [37] [38] [39] Lack of efficacy has generally been blamed on the acquired resistance of many tumor isolates to FasL-or TRAIL-mediated apoptosis. However, problems with vector delivery, sufficiently high transgene expression levels and the stability of the expressed protein may also play a significant role. Recently, we have reported development of a murine Fas ligand-green fluorescent protein (FasL-GFP) fusion protein, which we have shown to be stable, to have high apoptosis-inducing activity, and to be resistant to the metalloproteinase activity that in many tumor isolates cleaves off the extracytoplasmic C-terminus of human FasL. 31 We have put this protein under the control of a Tet-regulated promoter and have cloned both the FasL-GFP expression cassette and the Tet-regulated transcriptional activator protein expression cassette (using the CMV promoter) into a complex recombinant Ad5 vector. This combination resulted in high expression levels of the FasL-GFP protein under the induced conditions in all cultured cell lines and tumor isolates tested, and in the effective induction of apoptosis in several prostate cancer cell lines previously described as FasL-resistant. 29 In this study, we have constructed similar vectors expressing TRAIL or both FasL-GFP and TRAIL in a single adenoviral vector. We tested the ability of our vectors to induce apoptosis in several astrocytoma and glioblastoma isolates in vitro. We found that all cell lines were efficiently transduced by Ad5-based vectors, and that apoptosis was induced in the majority of the cell lines. With a few exceptions, sensitivity to TRAIL was lower than to FasL-GFP, but dual ligand vector was more active than either of the individual death ligand vectors, resistance to FasL-GFP activity correlated with a number of indicators, including low cell surface expression of Fas. Low levels of caspase-8, and elevated levels of FADD-like IL-1b-converting enzyme (FLICE) inhibiting proteins (FLIP).
Materials and methods

Cell lines
HeLa, HEK293 and A172 cells were obtained from the ATCC (CCL-2, CRL-1573 and CRL-1620, respectively). Remaining BT cell lines were obtained from the Brain Tumor Research Center Tissue Bank (Department of Neurological Surgery, UCSF, San Francisco, CA). Development and characterization of 293CrmA has been previously described. 31 All cell lines were maintained in DMEM supplemented with 10% cosmic calf serum (CCS; HyClone) and 1% penicillin/streptomycin. For DNA transfections, 5 Â 10 5 cells/well were seeded in six-well plates and transfected 24 hours later using LipofectAMINE (Gibco BRL) according to the manufacturer's instructions.
Infection of cultured cells with recombinant Ad vectors in vitro
Construction and characterization of Ad vectors expressing GFP and FasL-GFP have been described. 31, 40, 41 Vectors expressing TRAIL or both FasL-GFP and TRAIL were prepared using similar methods. All vectors were banded twice on CsCl gradients and desalted twice with a PD-10 size exclusion column (Amersham Scientific) into HBS (HEPES-buffered saline) þ 5% glycerol, and stored at À701C. Total vector particle counts (VP/ml) Death ligand gene therapy of brain tumor cells S Rubinchik et al were determined by measuring OD 260 in the presence of 0.2% SDS. All vectors were titrated on 293 cells for GFP fluorescence, monitored with Axiovert-25 fluorescent microscope (Zeiss) and FITC excitation/emission filter set (Chroma Technology Corp). The resulting titers were scored as infectious units (IU) per ml.
Detection of apoptosis
A measure of 5 Â 10 3 cells/well were seeded into 96-well plates. Next day, cells from four wells were counted to determine average cell number/well. Remaining wells were infected with Ad vectors at desired IU/cell ratios. After 48 hours, culture media were removed and replaced with 100 ml serum-free media plus 20 ml of MTS reagent (CellTiter96t Aqueous One Kit, Promega). Plates were incubated at 371C for 1 hour, and absorbance at 492 nm was measured for each well (related to number of viable cells) using FLUOSTARt dual fluorescence/absorbance plate reader (BMG labtechnologies). Ratio of absorbance in wells transduced with Ad vectors to that of uninfected cells was used to determine percent viable cells remaining in vectortreated wells.
Flow cytometry analysis of cell surface expression of FasR, DR4 and DR5
Near confluent cultures were washed twice with PBS and detached from 100 mm dishes with Cellstripper solution (Sigma). Cells were harvested and washed in DMEM containing 10% CCS. Cell pellets for each cell line were resuspended in 0.9 ml PBS and aliquoted evenly among four wells of a v-bottom 96-well microtiter plate (Nunc). Cells were pelleted (250 g, 5 min at 41C), and then resuspended and incubated for 1 hour at 41C in 50 ml/ well FACS buffer (3% BSA in PBS; filter sterilized) containing 10 mg/ml of either isotype control (MOPC-21; Sigma), anti-DR4 (HS101; Alexis Biochemicals), anti-DR5 (HS201; Alexis Biochemicals) or anti-Fas (ANC95.1/5E2; Alexis Biochemicals) primary antibody. Following incubation, wells were washed twice with 200 ml/well FACS buffer. Cell pellets were resuspended and incubated for 20 minutes at 41C (protected from light) in 50 ml/well R-PE goat anti-mouse IgG (Molecular Probes) secondary antibody diluted to 4 mg/ml in FACS buffer. Following incubation, cells were washed twice with 200 ml/well FACS buffer and resuspended in 400 ml total volume FACS buffer and analyzed using a Becton Dickinson FACSCalibur. Since HeLa expresses sufficient levels of Fas to be induced into apoptosis either by FasL or by agonistic mAbs, 31,42-44 they served as a positive control. A total of 20,000 events were scored for each cell line. Mean population fluorescence (correlating to level of Fas cell surface expression) was determined by subtracting mean fluorescence of isotype control from mean fluorescence of anti-Fas mAb for each cell line.
Western blot analysis
Near-confluent cultures were rinsed with PBS and lysed in RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1% SDS in PBS) containing a mammalian protease inhibitor cocktail (P-8340 Sigma, St Louis, MO). Lysates were stored at À701C and centrifuged (20,000 g) prior to performing protein assays on the supernatant (DC protein assay, BioRad, Hercules, CA). Protein (20 mg) was separated on 15-well 4-12% Bis/Tris NuPage gels in MES buffer (Novex/Invitrogen) and transferred to nitrocellulose (Bio-Rad) for 60-90 minutes at 30 V. Membranes were blocked in 5% milk in TBS-Tween for a minimum of 1 hour, and incubated with primary antibody in 0.5% milk (c-FLIP) or 5% milk (Caspase-8, Bax and actin) in TBS-Tween, overnight at 41C or at room temperature (anti-FLIP primary). Dilution and source of antibodies were as follows: Caspase-8 (1:2000, Alexis), Bax (1:250, Transduction Laboratories, Lexington, KY), c-FLIP (1:500 Dave-2, Alexis), actin (1:2000, Sigma). Following three washes with TBS-Tween, membranes were incubated with the appropriate HRPconjugated secondary antibodies: anti-mouse (1:5000), anti-rabbit (1:50,000, both from Santa Cruz Biotechnology Inc., Santa Cruz, CA), or anti-rat (1:15,000, Southern Biotechnology, Birmingham, AL). The membranes were washed three times in TBS-Tween followed by chemiluminescent detection of the secondary conjugates with DuraWest Supersignal (Pierce Biotechnology Inc., Rockford, IL).
Results
BT cell lines vary significantly in their sensitivity to FasL-GFP and TRAIL
We obtained a large panel of BT cell lines, derived from different stages of this disease (Table 1) , and proceeded to characterize them for sensitivity to FasL-GFP-and/or TRAIL-mediated apoptosis. Structures of all vectors used in this study are diagrammed in Figure 1 . In addition to 31 we constructed two vectors that express human TRAIL (rAd/TRL-I-GFP TET ) and both FasL-GFP and TRAIL (rAd/FasL-GFP TET TRL). These four vectors generate high transgene expression levels using the Tet-off gene regulation system. 45 All of them also incorporate the GFP reporter, allowing direct determination of IU in each vector preparation. HeLa, a well-characterized cell line that we previously established to be sensitive to FasL-mediated apoptosis, 31 was used as a positive control.
Each cell line was transduced at IU:cell ratio of 10 with each of the four vectors, and loss of cell viability was assayed 48 hours post-transduction using an MTS assay as described in Materials and methods. Figure 2 summarizes the results of this experiment. Cell line responses could be categorized into four groups. Three cell lines, including the HeLa control, were highly susceptible to both FasL-GFP and TRAIL activity (Fig 2a) , with the dual ligand vector providing only a minor increase in cytotoxicity. In U87MG, U251 and SF295, TRAIL was substantially less effective than FasL-GFP, while in in SF539 the opposite was observed (Fig 2b) . Again, dual ligand vector generated apoptosis levels comparable to those of the more active ligand. Two of the cell lines, U343MG and U373MG, proved to be essentially resistant to both ligands, either independently or jointly delivered (Fig 2d) . The most interesting response was observed in five cell lines (A172, SF126, SF188, SF268 and SF763) where rAd/FasL-GFP TET TRL was substantially more effective than either of the individual ligand vectors (Fig 2c) .
In general, we found that seven out of 13 cell lines were sensitive to FasL-GFP (greater than 50% cells dead), with one being more partially sensitive (between 20 and 50% cell death). Only three cell lines were sensitive to TRAIL, with seven cell lines being partially sensitive. In compar- 
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ison, eight cell lines were sensitive and three were partially sensitive to dual ligand vector, with only U343MG and U373MG being truly resistant. As well, rAd/FasL-GFP TET TRL vector elicited comparatively more cytoxicity in all cell lines tested in this study. The control vector rAd/GFP TET typically generated o10% cell death in this experiment (Fig 2) .
Proapoptotic interaction of FasL-GFP and TRAIL appears to be synergistic in some cell lines Levels of apoptosis induced by the rAd/FasL-GFP TET TRL in five out of 13 BT cell lines were substantially higher than those generated by either of the individual ligand vectors. For example, SF763 represents the prototypical cell line for such an effect. However, transduction of U251MG with rAd/FasL-GFP TET TRL did not greatly enhance the cytotoxicity that resulted from transduction with the FasL-GFPexpressing vector. To examine this effect in more detail, we performed dose-response studies in SF763 and U251MG cells, and determined vector to cell ratios at which 50% cell death (LD 50 ) was reached (Fig 3) . In this study, SF763 and U251MG cells were infected with either (1) rAd/GFP TET , (2) rAd/FasL-GFP TET , (3) rAd/TRL-I-GFP TET , (4) rAd/FasL-GFP TET plus rAd/TRL-I-GFP TET or (5) the dual vector, rAd/FasL-GFP TET TRL. Since condition 4 (rAd/FasL-GFP TET plus rAd/TRL-I-GFP TET ) was a coinfection with two recombinant Ad vectors, the IU/cell ratios were equalized in the other conditions by coinfection of equal IU/cell ratios of rAd/ GFP. In SF763 cells, rAd/FasL-GFP TET TRL vector reached LD 50 at an IU:cell ratio of 18, while either FasL-GFP or TRAIL expressing vectors required IU:cell ratios of 85. Thus, the dual ligand vector was able to achieve the same level of cytotoxic activity at a five-fold lower IU dose, strongly suggesting that synergistic interactions between FasL-GFP and TRAIL were enhancing apoptosis in SF763 (Fig 3, left panel) . In contrast, activity of rAd/ FasL-GFP TET TRL in U251MG cells (Fig 3, right panel) was essentially the same as that of the rAd/FasL-GFP TET vector (LD 50 of 9.5 and 12, respectively), with rAd/TRL-I-GFP TET being less effective (LD 50 of 28). Therefore, a clear difference appears to exist between BT cell lines in their responses to combined FasL-GFP and TRAIL activity.
BT cell lines are efficiently transduced by Ad5-based vectors
Reduced sensitivity to FasL-GFP and/or TRAIL was observed in SF295, SF539, SF268 and SF763, while U343MG and U373MG were found to be essentially resistant. In order to better understand the mechanisms of this resistance, we investigated some of the factors that could cause it. An important requirement for inducing apoptosis in BT cells with Ad-mediated gene transfer is the efficiency with which those cells are infected. This process requires the presence of both primary and secondary receptors for the Ad5 virion (i.e., CAR and a 3 b V or a 5 b V integrins) on the cell surface at levels sufficient to allow binding by the vector. 46, 47 As most of the clinical tumor cell isolates are heterogeneous, we have tested all our cell lines for susceptibility to Ad5 vector infection by titrating the replication competent rcAd/ CMV-GFP vector on each of the cell lines (Fig 4) . The ability of rcAd/CMV-GFP to replicate in all human cell lines allows for an easy detection of transduced cells, since vector genome amplification boosts GFP expression levels many fold. As shown in Figure 4 , half of cell lines were transduced as well or better than the HeLa control, while Figure 3 Codelivery of FasL and TRAIL expression to the same cell results in synergistic apoptotic activity in some, but not all, BT cell lines. SF763 and U251MG cells were seeded and transduced with indicated vectors at indicated IU:cell ratios as described in Materials and methods. rAd/GFP TET was added to the single cytotoxic vectors to equalize total IU values. Loss of cell viability was determined and reported as described in Figure 2 . Intersections of 50% cell death and vector-to-cell ratio were used to determine LD 50 values. HaLa  A172  U87MG  U251MG  U343MG  U373MG  SF126  SF188  SF210  SF268  SF295  SF539  SF763  SF767 14. Relative Infectivity Ratio Figure 4 Ad5-based vectors efficiently transduce BT cell lines.
Relative infectivity ratio values were determined by titrating a characterized preparation of replication competent rcAd/CMV-GFP vector on each of the cell lines. The titer obtained on HeLa cells (1.3 Â 10 9 IU/ml) was arbitrarily assigned an infectivity value of 1, and other values were determined by dividing each established titer by that of HeLa.
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the others were on average only 50% less transducible. It is therefore unlikely that poor infection is the cause of low sensitivity to death ligand vectors.
Resistance to vector-mediated apoptotis correlates to Fas receptor density but not to that of TRAIL receptors
Another factor that could influence cell sensitivity to death ligands is the level of cell surface receptors. 46, 47 We determined cell surface levels of FasR and DR4 and DR5 (functional TRAIL receptors) for each cell line using flow cytometry (Fig 5) . The majority of cell lines had levels of FasR comparable to or greater than those of HeLa. Interestingly, cell lines partially resistant to FasL-GFP (SF268 and SF763) had significantly reduced FasR levels, and completely FasL-resistant cell line SF539 had no detectable cell surface FasR expression. A similar correlation was not found between DR4 and/or DR5 and resistance to TRAIL (Fig 5) . Interestingly, the two most highly resistant cell lines, U343MG and U373MG, expressed both high levels of FasR and had higher DR5 levels than the TRAILsensitive HeLa control (Fig 5) .
Resistance to death ligand activity correlates with reduced levels of caspase-8 and increased levels of c-FLIP isoforms
We proceeded to determine the levels of some of the other components of the ''death ligand'' apoptotic pathway by Western blot, specifically caspase-8, an initiator caspase of the Fas signaling pathway 48, 49 and c-FLIP isoforms. Both large and small c-FLIP can form inactive heterodimers with caspase-8 (FLICE), and thus act as apoptosis inhibitors early in the pathway. 50, 51 As Figure 6 demonstrates, FasL-sensitive cell lines such as SF767 and SF295 have high levels of caspase-8 and very low levels of c-FLIP isoforms. In contrast, FasL-resistant U343MG and U373MG were found to have much lower caspase-8 levels, while at the same time their levels of c-FLIP isoforms were significantly increased. Interestingly, SF268 had caspase-8 and c-FLIP levels halfway between SF767 and U373MG, while SF763 had high caspase-8 and low c-FLIP levels, a pattern similar to that of sensitive SF767 cells. In general, we found that resistance to both FasL-GFP-and TRAIL-mediated apoptosis in BT cell lines that expressed cell surface receptors for both ligands correlated with low caspase-8:c-FLIP ratio. However, the reason for generally lower sensitivity to TRAIL was not apparent. Cell lines were examined for expression of proapoptotic Bax protein, which has been reported to be required for TRAIL-mediated apoptosis in some cell lines. 52, 53 All cell lines we tested expressed substantial amounts of Bax (Fig 6) , and again no correlation was found between relative Bax levels and TRAIL sensitivity.
Discussion
Currently, no effective treatment options are available for the therapy of the most malignant BTs. Surgical removal of the tumor mass, which is mandatory for precise diagnosis, improves the prognosis, although the infiltrative behavior of malignant gliomas precludes their complete resection, and in 90% of cases tumor recurs HaLa  A172  U87MG  U251MG  U343MG  U373MG  SF126  SF188  SF210  SF268  SF295  SF539  SF763 Death ligand gene therapy of brain tumor cells S Rubinchik et al within 2 cm from the primary site. Postoperative radiotherapy and/or chemotherapy is therefore commonly administered and somewhat improves survival. However, few patients survive 2 years after diagnosis. Results of chemotherapy trials as well as gene therapy trials using prodrug-converting enzymes are disappointing due to the tumor's intrinsic chemoresistance 54, 55 and its localization within the central nervous system, which limits the penetration of drugs. An alternative approach, referred to as ''molecular surgery'', has been formulated and promises effective therapy, reduced surgical damage to the normal brain tissue and fewer side effects. The therapeutic vectors may be directly injected into a tumor by a needle through the brain cortex, rather than removal of some of the normal brain tissue to access the tumor surgically. To realize this conceptual therapy, different approaches have been studied, and some have shown promising results in animal models, such as vectormediated HSVtk gene transfer [56] [57] [58] or infection with HSV that specifically replicates in tumor cells. 59, 60 In this study, we have compared the efficacy of Ad vector-mediated delivery of FasL-GFP, human TRAIL, and both death ligands using a single vector. We have shown that Ad-mediated transfer of these proteins can efficiently induce apoptosis of polymorphic tumor cells derived from high-grade malignant BT isolates. All of the cell lines we have tested could be efficiently transduced with Ad5-based vectors (Fig 4) . Specifically, resistance of SF268, SF763, SF539, U343MG and U373MG to vectormediated apoptosis could not be ascribed to inefficient transduction. The susceptibilities to FasL-and TRAILmediated apoptosis differed among the cells from different tumor isolates. By and large, resistance to FasL-GFP activity in the cell lines we have tested correlated with low Fas cell surface levels and/or with low caspase-8/c-FLIP isoforms ratios. Caspase-8 is an initiator caspase that is recruited to the DISC formed at the death receptor. Cleavage of caspase-8 into its active form is critical for the apoptotic signal to proceed. c-FLIP is a caspase-8 homolog that lacks the active center and behaves as a dominant-negative inhibitor of caspase-8. Therefore, the ratio between caspase-8 and its homolog c-FLIP may determine whether the apoptotic signal proceeds or is aborted.
We utilized Western blotting to compare levels of caspase-8 and c-FLIP isoforms (55 and 26 kDa) to determine whether a correlation exists between caspase-8/c-FLIP ratio and susceptibility to death ligands. Cell lines that were highly susceptible to both FasL and TRAIL (SF767 and SF210) expressed high levels of caspase-8 and low levels of c-FLIP, whereas cells that were resistant to both death ligands (U343MG and U373MG) expressed low levels of caspase-8 and high levels of at least one c-FLIP isoform. Based on our results, as well as those published previously, 34, 61, 62 we conclude that while the majority of BTs have a functional Fas and/or TRAIL apoptotic pathway, a certain fraction of them (between 25 and 35%) are resistant through a number of different apoptotic pathway alterations. [37] [38] [39] [61] [62] [63] [64] However, high caspase-8:c-FLIP ratio was not in itself indicative of high sensitivity to either FasL-GFP or to TRAIL. These observations are consistent with the general mechanism of receptor-ligand-mediated signal transduction, where multiple components have to interact to propagate the signal, and conversely the signal can be blocked or degraded by mutations or dysregulation of those components. BT cell lines were, in general, less sensitive to TRAIL, and levels of TRAIL sensitivity did not appear to correlate with either cell surface expression levels of DR4 and DR5, or with levels of Bax. FasL-GFP and TRAIL were effective against eight out of 13 and six out of 13 BT cell lines, respectively. In contrast, combined delivery of both ligands was effective against 11 out of 13 cell lines, and in general generated the highest cytotoxicity levels in all cell lines tested. Interestingly, coinfection of cells with two vectors each expressing one death ligand was not as effective as a single vector delivering both genes together (Fig 3) .
In five cell lines, codelivery of FasL-GFP and TRAIL generated synergistic cytotoxic activity, suggesting a potential interaction of more than one apoptotic pathway. Although both ligands are thought to interact through FADD protein and caspase-8 (DISC complex), it is possible that TRAIL may be signaling through additional adaptors (such as TRADD). Similar proapoptotic synergy was observed between Fas and TNFR signaling pathways in prostate cancer LNCaP cells, but the exact mechanisms have not yet been elucidated. 65 These synergistic interactions were not universal in the BT cell lines we tested, but occurred in roughly 40% of them -a significant fraction. The mechanism of this synergistic interaction will be investigated in future studies.
In conclusion, we have shown that Ad-mediated delivery of FasL-GFP was more effective than that of TRAIL, while FasL-GFP plus TRAIL was more effective than either ligand alone. Using the dual ligand vector, 85% of high-grade malignant BT cell lines could be forced into apoptosis by vector-mediated expression of FasL-GFP and TRAIL. Our data suggested that Ad-mediated gene transfer of multiple death ligands (as well as other cytotoxic genes) can be employed to overcome inherent heterogeneity of BT cells and achieve a more effective therapy than single cytotoxic gene strategies. This approach can be developed into an effective component in the overall context of BT gene therapy.
Abbreviations
CrmA, cytokine response modifier A; DD, death domain; DED, death effector domain; DR, death receptor; DcR, decoy receptor; DISC, death-inducing signaling complex; FasL-GFP, Fas ligand-green fluorescent protein fusion; FLICE, Fas-associated death domain-like IL-1b-converting enzyme; FLIP, FLICE-inhibitory protein; NF-kB, nuclear factor kappa B; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis inducing ligand.
